By explicitly relating our validated miRNA panel to established IBD- and CRC-associated miRNAs (including miR-155 and miR-223) and to key pathways such as NF-κB and JAK–STAT, we position our findings within the current literature and emphasize that the miRNA–cytokine–T-cell axis described here is a plausible mechanistic link between inflammation control, immune dysregulation, and early CRC-related changes in IBD. Here, NFKB1 is linked to colorectal carcinoma.